These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 36200910)
21. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay. Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312 [TBL] [Abstract][Full Text] [Related]
22. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525 [TBL] [Abstract][Full Text] [Related]
23. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics]. Haupts A; Roth W; Hartmann N Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045 [TBL] [Abstract][Full Text] [Related]
24. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer. Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812 [TBL] [Abstract][Full Text] [Related]
25. Aberrant circulating tumor DNA methylation and exosomal microRNA biomarkers for early detection of colorectal cancer. Zhang X; Hou H; Jiang M; Zhang X Mol Biol Rep; 2023 Mar; 50(3):2743-2750. PubMed ID: 36583782 [TBL] [Abstract][Full Text] [Related]
26. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). Garlan F; Laurent-Puig P; Sefrioui D; Siauve N; Didelot A; Sarafan-Vasseur N; Michel P; Perkins G; Mulot C; Blons H; Taieb J; Di Fiore F; Taly V; Zaanan A Clin Cancer Res; 2017 Sep; 23(18):5416-5425. PubMed ID: 28576867 [No Abstract] [Full Text] [Related]
27. Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1. Symonds EL; Pedersen SK; Yeo B; Al Naji H; Byrne SE; Roy A; Young GP Mol Oncol; 2022 May; 16(10):2031-2041. PubMed ID: 35000264 [TBL] [Abstract][Full Text] [Related]
28. Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer. Benavides M; Alcaide-Garcia J; Torres E; Gil-Calle S; Sevilla I; Wolman R; Durán G; Álvarez M; Reyna-Fortes C; Ales I; Pereda T; Robles M; Kushnir M; Odegaard J; Faull I; Alba E ESMO Open; 2022 Jun; 7(3):100481. PubMed ID: 35525184 [TBL] [Abstract][Full Text] [Related]
29. Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. Jin S; Zhu D; Shao F; Chen S; Guo Y; Li K; Wang Y; Ding R; Gao L; Ma W; Lu T; Li D; Zhang Z; Cai S; Liang X; Song H; Ji L; Li J; Zheng Z; Jiang F; Wu X; Luan J; Zhang H; Yang Z; Cantor CR; Xu C; Ding C Proc Natl Acad Sci U S A; 2021 Feb; 118(5):. PubMed ID: 33495330 [TBL] [Abstract][Full Text] [Related]
30. The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. Manca P; Corallo S; Busico A; Lonardi S; Corti F; Antoniotti C; Procaccio L; Clavarezza M; Smiroldo V; Tomasello G; Murialdo R; Sartore-Bianchi A; Racca P; Pagani F; Randon G; Martinetti A; Sottotetti E; Palermo F; Perrone F; Tamborini E; Prisciandaro M; Raimondi A; Di Bartolomeo M; Morano F; Pietrantonio F Clin Cancer Res; 2021 May; 27(9):2505-2514. PubMed ID: 33547199 [TBL] [Abstract][Full Text] [Related]
31. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes. Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618 [TBL] [Abstract][Full Text] [Related]
32. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients. Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985 [TBL] [Abstract][Full Text] [Related]
33. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data. Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327 [TBL] [Abstract][Full Text] [Related]
34. Concordance analysis between liquid biopsy (ctDNA) and tumor DNA molecular profiles from panel-based next-generation sequencing. Rodon Font N; No Garbarino Y; Díaz Castello O; Moya Amoros J; Barrios Sánchez P; Coroleu Lletget D; Lequerica Cabello MA; Borras Marcet J; Mecho Meca S; Escape I; Martinez-Agea J; Garcia E; Ferrer M; Puig Torrus X Rev Esp Patol; 2022; 55(3):156-162. PubMed ID: 35779881 [TBL] [Abstract][Full Text] [Related]
35. The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. Wong R; Tie J; Lee M; Cohen J; Wang Y; Li L; Ma S; Christie M; Kosmider S; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P Int J Cancer; 2019 Jul; 145(2):540-547. PubMed ID: 30628066 [TBL] [Abstract][Full Text] [Related]
36. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Bachet JB; Bouché O; Taieb J; Dubreuil O; Garcia ML; Meurisse A; Normand C; Gornet JM; Artru P; Louafi S; Bonnetain F; Thirot-Bidault A; Baumgaertner I; Coriat R; Tougeron D; Lecomte T; Mary F; Aparicio T; Marthey L; Taly V; Blons H; Vernerey D; Laurent-Puig P Ann Oncol; 2018 May; 29(5):1211-1219. PubMed ID: 29438522 [TBL] [Abstract][Full Text] [Related]
37. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661 [TBL] [Abstract][Full Text] [Related]
38. Enhanced Performance of DNA Methylation Markers by Simultaneous Measurement of Sense and Antisense DNA Strands after Cytosine Conversion. Jensen SØ; Øgaard N; Nielsen HJ; Bramsen JB; Andersen CL Clin Chem; 2020 Jul; 66(7):925-933. PubMed ID: 32460325 [TBL] [Abstract][Full Text] [Related]
39. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection. Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556 [TBL] [Abstract][Full Text] [Related]
40. Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients. Yang YC; Wang D; Jin L; Yao HW; Zhang JH; Wang J; Zhao XM; Shen CY; Chen W; Wang XL; Shi R; Chen SY; Zhang ZT Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29914973 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]